Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
Journal of Virology · 18.03.2025 · 99 (3)
DOI: 10.1128/jvi.01623-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, erschienen am 18.03.2025. Verfasst von Tin Phan und 24 weiteren Autor:innen. Beteiligte Einrichtung: Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, USA. Hauptthemen laut MEDLINE: Ritonavir, SARS-CoV-2, COVID-19 Drug Treatment, Antiviral Agents. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, HHS | National Institutes of Health.
Abstract (Originalsprache)
In a subset of SARS-CoV-2-infected individuals treated with the antiviral nirmatrelvir-ritonavir, the virus rebounds following treatment. The mechanisms driving this rebound are not well understood. We used a mathematical model to describe the longitudinal viral load dynamics of 51 individuals treated with nirmatrelvir-ritonavir, 20 of whom rebounded. Target cell preservation, either by a robust innate immune response or initiation of N-R near the time of symptom onset, coupled with incomplete viral clearance, appears to be the main factor leading to viral rebound. Moreover, the occurrence of viral rebound is likely influenced by the time of treatment initiation relative to the progression of the infection, with earlier treatments leading to a higher chance of rebound. A comparison with an untreated cohort suggests that early treatments with nirmatrelvir-ritonavir may be associated with a delay in the onset of an adaptive immune response. Nevertheless, our model demonstrates that extending the course of nirmatrelvir-ritonavir treatment to a 10-day regimen may greatly diminish the chance of rebound in people with mild-to-moderate COVID-19 and who are at high risk of progression to severe disease. Altogether, our results suggest that in some individuals, a standard 5-day course of nirmatrelvir-ritonavir starting around the time of symptom onset may not completely eliminate the virus. Thus, after treatment ends, the virus can rebound if an effective adaptive immune response has not fully developed. These findings on the role of target cell preservation and incomplete viral clearance also offer a possible explanation for viral rebounds following other antiviral treatments for SARS-CoV-2. IMPORTANCE Nirmatrelvir-ritonavir is an effective treatment for SARS-CoV-2. In a subset of individuals treated with nirmatrelvir-ritonavir, the initial reduction in viral load is followed by viral rebound once treatment is stopped. We show that the timing of treatment initiation with nirmatrelvir-ritonavir may influence the risk of viral rebound. Nirmatrelvir-ritonavir stops viral growth and preserves target cells but may not lead to full clearance of the virus. Thus, once treatment ends, if an effective adaptive immune response has not adequately developed, the remaining virus can lead to rebound. Our results provide insights into the mechanisms of rebound and can help develop better treatment strategies to minimize this possibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, USA.
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
- Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
- Africa Health Research Institute, KwaZulu-Natal, South Africa.
ORCID-Profile: Tin Phan, Ruy M Ribeiro, Jatin M Vyas, Amy K Barczak, Alan S Perelson
Förderung
- NIAID NIH HHS
- NHLBI NIH HHS
- HHS | National Institutes of Health
- DOE | NNSA | Los Alamos National Laboratory
- Massachusetts Consortium on Pathogen Readiness
- Massachusetts General Hospital Department of Medicine
Zitieren
APA
Phan, T., Ribeiro, R. M., Edelstein, G. E., Boucau, J., Uddin, R., Marino, C., Liew, M. Y., Barry, M., Choudhary, M. C., Tien, D., Su, K., Reynolds, Z., Li, Y., Sagar, S., Vyas, T. D., Kawano, Y., Sparks, J. A., Hammond, S. P., Wallace, Z., …, & Perelson, A. S. (2025). Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance. Journal of Virology, 99(3). https://doi.org/10.1128/jvi.01623-24
Vancouver
Phan T, Ribeiro RM, Edelstein GE, Boucau J, Uddin R, Marino C, et al. Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance. Journal of Virology. 2025;99(3). doi:10.1128/jvi.01623-24
BibTeX
@article{Phan2025,
author = {Phan, Tin and Ribeiro, Ruy M and Edelstein, Gregory E and Boucau, Julie and Uddin, Rockib and Marino, Caitlin and Liew, May Y and Barry, Mamadou and Choudhary, Manish C and Tien, Dessie and Su, Karry and Reynolds, Zahra and Li, Yijia and Sagar, Shruti and Vyas, Tammy D and Kawano, Yumeko and Sparks, Jeffrey A and Hammond, Sarah P and Wallace, Zachary and Vyas, Jatin M and Li, Jonathan Z and Siedner, Mark J and Barczak, Amy K and Lemieux, Jacob E and Perelson, Alan S},
title = {Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance},
journal = {Journal of Virology},
year = {2025},
volume = {99},
number = {3},
doi = {10.1128/jvi.01623-24}
}
EUVIMED